UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
DMB Number:	3235-0287				
Estimated average burden nours per response 0.5					
ours per response					

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)													
1. Name and Address of Reporting Person * SETH SANDESH				2. Issuer Name and Ticker or Trading Symbol Actinium Pharmaceuticals, Inc. [ATNM]					1	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O ACTINIUM PHARMACEUTICALS, INC, 501 FIFTH AVENUE, THIRD FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 08/08/2013					-		r (give title belo		Other (specify be	low)	
(Street) NEW YORK, NY 10017			4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) X. Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City		(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficia					Beneficially	Owned					
(Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if) any (Month/Day/Year)		f Code (Instr. 8)		tion 4. Securities Acqui (A) or Disposed of (D) (Instr. 3, 4 and 5)		of			Following	Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
						Cod	e V	Amou	(A) or (D)	Price				or Indirect (I) Instr. 4)	Instr. 4)
Restricted	l Stock (1)		08/08/2013			A		10,00		\$ 3.6	0			D	
Reminder: indirectly.	Report on a	separate line fo	Table II - D	erivative	Securiti	es Acqui	Person the	sons w tained form di isposed	in this for splays a	m are curre eficial	not req	uired to re	oformation espond unl ntrol numb	ess	C 1474 (9- 02)
Security	Conversion	3. Transaction Date (Month/Day/Y	n 3A. Deemed Execution Day any	4. Transaction Code Year) (Instr. 8)		5. Numb	over 6. I and (Mores d	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Ti Amo Undo Secu (Inst 4)	ount of erlying urities r. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Ownership Form of Derivative Security: Direct (D) or Indirect	
				Co	ode V	(A) (I		e ercisable	Expiration Date	Title	Number of Shares				
Repor	ting O	wners													

Donatha Oman Vana / Addam	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
SETH SANDESH C/O ACTINIUM PHARMACEUTICALS, INC 501 FIFTH AVENUE, THIRD FLOOR NEW YORK, NY 10017	X					

Signatures

/s/ Sandesh Seth	12/24/2013
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 100% of the Restricted Stocks vests 12 months after the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

